You are here:

Forthcoming Submission: tivozanib (Fotivda)

Indication: For the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

Drug Details

Drug Name: tivozanib (Fotivda)
Drug Manufacturer: EusaPharma
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
2/04/2018
SMC Meeting Date: Q2 2018
Advice Due: Q3 2018

Back